Search

Displaying results 3471 - 3480 of 10000 in total
  1. Drug

    Chlorphenoxamine

    go.drugbank.com/drugs/DB09007
    ApprovedWithdrawn

    Chlorphenoxamine is marketed under the name Phenoxene. It is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.

    Synonyms: -PHENYLBENZYL)OXY)-N,N-DIMETHYLETHYLAMINE, ETHENAMINE, 2-(1-(4-CHLOROPHENYL)-1-PHENYLETHOXY)-N,N-DIMETHYL-Categories: Antihistamines for Topical Use, Antihistamines for Systemic Use
  2. Drug

    Cortisone acetate

    go.drugbank.com/drugs/DB01380
    ApprovedInvestigational

    Cortisone acetate was first isolate in 1935 and became more widely researched in 1949. … [A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.[L15107]

    Categories: Corticosteroids for Systemic Use
  3. Drug

    Hydroxyamphetamine

    go.drugbank.com/drugs/DB09352
    Approved

    Hydroxyamphetamine is a derivative of amphetamines. Hydroxyamphetamine is intended mainly as local eye drops for diagnostic purposes. … Among the minor side effects from its use are: change in color vision, difficulty seeing at night, dry mouth, headache, increased sensitivity of eyes to sunlight, muscle stiffness or tightness and temporary

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. … [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary

  5. Drug

    Tamibarotene

    go.drugbank.com/drugs/DB04942
    Investigational

    Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States. … Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL).

  6. Drug

    Regadenoson

    go.drugbank.com/drugs/DB06213
    ApprovedInvestigational

    Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

    Products: Lexiscan(r) (regadenoson)
  7. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. … Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19.

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING, A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING O
  8. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    [A275521,A275522] On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior … It is the first BCL-2 inhibitor approved for MCL and the second oncology-approved BCL-2 inhibitor overall, following venetoclax.

    Synonyms: N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3- nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin- 1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5- yl
  9. Drug

    Antazoline

    go.drugbank.com/drugs/DB08799
    Approved

    It is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis. … Antazoline is a 1st generation antihistamine with anticholinergic activity. It is used to relieve nasal congestion.

    Categories: Antihistamines for Systemic UseSynonyms: 2-(N-Phenyl-N-benzylaminomethyl)imidazoline, 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine
  10. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Most recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953] … It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries.